Yan Huang

7PUBLICATIONS

45CO-AUTHORS

Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (7)

Sort by Publication Date:

|Jul 13, 2026

BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for <i>EGFR</i>-mutated advanced non-small-cell lung cancer: a phase 1b trial.

|Mar 24, 2026

The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer.

Jiani Zheng, Shen Zhao, Jianhua Zhan

|Apr 22, 2025

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Jinhui Xue, Yuxiang Ma, Yuanyuan Zhao

|May 21, 2024

Integrated analysis of single-cell and bulk RNA sequencing data reveals a myeloid cell-related regulon predicting neoadjuvant immunotherapy response across cancers.

Hong Liu, Xiaoxian Sima, Bijing Xiao

|May 10, 2024

Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.

Bijing Xiao, Guanjun Li, Haimiti Gulizeba

|Jan 23, 2024

Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non-Small Cell Lung Cancer.

Shaoxing Guan, Xi Chen, Yuru Wei

Pageof 2

Frequent Collaborators

Hongyun Zhao

Yuanyuan Zhao

Li Zhang

Yunpeng Yang

Wenfeng Fang

Shaodong Hong

Jinhui Xue

Xi Chen

Jiuwei Cui

Wen Xie

Frequent Collaborators

Hongyun Zhao

Yuanyuan Zhao

Li Zhang

Yunpeng Yang